We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Presents Data on Utomilumab for Solid Tumors
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced results from a phase Ib study on utomilumab (PF-05082566) for the treatment of advanced solid tumors.
The dose-escalation study evaluated the overall safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of utomilumab, in combination with Merck & Co. Inc.’s (MRK - Free Report) Keytruda (pembrolizumab), in patients (n~23) with advanced solid tumors including non-small cell lung cancer, renal cell carcinoma, head and neck cancers, pancreatic cancer, anaplastic thyroid cancer, small-cell lung cancer, colon cancer, sarcoma, thymoma and melanoma.
Data from the study revealed that two patients – one with small cell lung cancer and the other with renal cell carcinoma – confirmed complete response. In addition, partial responses were observed in four patients – one each with renal cell carcinoma, non-small cell lung cancer, head and neck cancer and anaplastic thyroid cancer.
Adverse events related to treatment were reported to be mild and did not appear to increase with higher doses of utomilumab. Moreover, no dose-limiting toxicity was reported. Data from the study were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Meanwhile, utomilumab is being evaluated in several studies in both hematologic cancers and solid tumors. Utomilumab, as monotherapy, is currently being evaluated across multiple tumors. The candidate is also being evaluated in combination with Rituxan (rituximab) for the treatment of lymphoma and in combination with mogamulizumab for the treatment of advanced solid tumors.
Utomilumab, in combination with other immunotherapies, is also being studied for various solid tumors and hematological malignancies.
Pfizer currently sports a Zacks Rank #1 (Strong Buy). Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) are two other favorably placed stocks in the health care sector, both carrying the same Zacks Rank as Pfizer.
Image: Bigstock
Pfizer (PFE) Presents Data on Utomilumab for Solid Tumors
Pfizer Inc. (PFE - Free Report) announced results from a phase Ib study on utomilumab (PF-05082566) for the treatment of advanced solid tumors.
The dose-escalation study evaluated the overall safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of utomilumab, in combination with Merck & Co. Inc.’s (MRK - Free Report) Keytruda (pembrolizumab), in patients (n~23) with advanced solid tumors including non-small cell lung cancer, renal cell carcinoma, head and neck cancers, pancreatic cancer, anaplastic thyroid cancer, small-cell lung cancer, colon cancer, sarcoma, thymoma and melanoma.
Data from the study revealed that two patients – one with small cell lung cancer and the other with renal cell carcinoma – confirmed complete response. In addition, partial responses were observed in four patients – one each with renal cell carcinoma, non-small cell lung cancer, head and neck cancer and anaplastic thyroid cancer.
Adverse events related to treatment were reported to be mild and did not appear to increase with higher doses of utomilumab. Moreover, no dose-limiting toxicity was reported. Data from the study were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Meanwhile, utomilumab is being evaluated in several studies in both hematologic cancers and solid tumors. Utomilumab, as monotherapy, is currently being evaluated across multiple tumors. The candidate is also being evaluated in combination with Rituxan (rituximab) for the treatment of lymphoma and in combination with mogamulizumab for the treatment of advanced solid tumors.
Utomilumab, in combination with other immunotherapies, is also being studied for various solid tumors and hematological malignancies.
Pfizer currently sports a Zacks Rank #1 (Strong Buy). Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) are two other favorably placed stocks in the health care sector, both carrying the same Zacks Rank as Pfizer.
Want the latest recommendations from Zyes i have
acks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>